126 related articles for article (PubMed ID: 3298136)
21. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.
Talpaz M; Kantarjian HM; McCredie K; Trujillo JM; Keating MJ; Gutterman JU
N Engl J Med; 1986 Apr; 314(17):1065-9. PubMed ID: 3457264
[TBL] [Abstract][Full Text] [Related]
22. Interferon alfa-2b and chlorambucil in the treatment of non-Hodgkin's lymphoma.
Chisesi T; Capnist G; Vespignani M; Cetto G
Invest New Drugs; 1987; 5 Suppl():S35-40. PubMed ID: 3298132
[TBL] [Abstract][Full Text] [Related]
23. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
24. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
[TBL] [Abstract][Full Text] [Related]
25. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report.
Pangalis GA; Griva E
Cancer; 1988 Mar; 61(5):869-72. PubMed ID: 3338053
[TBL] [Abstract][Full Text] [Related]
26. Combination trial of subcutaneous interferon alfa-2b and oral cyclophosphamide in favorable histology, non-Hodgkin's lymphoma.
Ozer H; Anderson JR; Peterson BA; Budman DR; Henderson ES; Bloomfield CD; Gottlieb A
Invest New Drugs; 1987; 5 Suppl():S27-33. PubMed ID: 3298131
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A).
Volberding PA; Mitsuyasu RT; Golando JP; Spiegel RJ
Cancer; 1987 Feb; 59(3 Suppl):620-5. PubMed ID: 3492260
[TBL] [Abstract][Full Text] [Related]
28. Interferon alfa-2b therapy in untreated early stage, B-chronic lymphocytic leukaemia patients: one-year follow-up.
Boussiotis VA; Pangalis GA
Br J Haematol; 1991 Oct; 79 Suppl 1():30-3. PubMed ID: 1931705
[TBL] [Abstract][Full Text] [Related]
29. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
Ratain MJ; Golomb HM; Vardiman JW; Westbrook CA; Barker C; Hooberman A; Bitter MA; Daly K
J Clin Oncol; 1988 Nov; 6(11):1714-21. PubMed ID: 3054003
[TBL] [Abstract][Full Text] [Related]
30. [Observation of long-term therapeutic outcome in chronic granulocytic leukemia].
Liu B; Wang Y; Hao C; Liu Y; Qian L
Zhonghua Xue Ye Xue Za Zhi; 2001 Feb; 22(2):61-3. PubMed ID: 11877049
[TBL] [Abstract][Full Text] [Related]
31. The use of interferon in the treatment of multiple myeloma.
Costanzi JJ; Pollard RB
Semin Oncol; 1987 Jun; 14(2 Suppl 2):24-8. PubMed ID: 3296211
[TBL] [Abstract][Full Text] [Related]
32. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.
; Tura S; Baccarani M; Zuffa E; Russo D; Fanin R; Zaccaria A; Fiacchini M
N Engl J Med; 1994 Mar; 330(12):820-5. PubMed ID: 8114834
[TBL] [Abstract][Full Text] [Related]
33. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy.
Mandelli F; Avvisati G; Amadori S; Boccadoro M; Gernone A; Lauta VM; Marmont F; Petrucci MT; Tribalto M; Vegna ML
N Engl J Med; 1990 May; 322(20):1430-4. PubMed ID: 2184356
[TBL] [Abstract][Full Text] [Related]
34. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia.
Mirro J; Dow LW; Kalwinsky DK; Dahl GV; Weck P; Whisnant J; Murphy SB
Cancer Treat Rep; 1986 Mar; 70(3):363-7. PubMed ID: 3456833
[TBL] [Abstract][Full Text] [Related]
35. [Therapy of chronic myeloid leukemia with interferon].
Fülle HH; Dahmen E; Hellriegel KP
Onkologie; 1988 Aug; 11(4):177-83. PubMed ID: 3054669
[TBL] [Abstract][Full Text] [Related]
36. [Prospective controlled study of therapy of chronic myeloid leukemia (CML)].
Hehlmann R; Heimpel H; Hossfeld DK; Köpcke W; Kolb HJ; Löffler H; Pralle H; Queisser W; Anger B; Bergmann L
Onkologie; 1987 Feb; 10(1):28-33. PubMed ID: 3295623
[TBL] [Abstract][Full Text] [Related]
37. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia.
Herrmann F; Helfrich SG; Lindemann A; Schleiermacher E; Huber C; Mertelsmann R
J Clin Oncol; 1992 Apr; 10(4):631-4. PubMed ID: 1548526
[TBL] [Abstract][Full Text] [Related]
38. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity.
Oberg K; Alm G; Magnusson A; Lundqvist G; Theodorsson E; Wide L; Wilander E
J Natl Cancer Inst; 1989 Apr; 81(7):531-5. PubMed ID: 2466128
[TBL] [Abstract][Full Text] [Related]
39. [Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Armenta D; Espallargas C; Paz A; Rodríguez Martorel J; Ladines R; Alvarez C; Román J; Andrés P
Sangre (Barc); 1996 Dec; 41(6):465-7. PubMed ID: 9148424
[TBL] [Abstract][Full Text] [Related]
40. Interferon alfa-2b in acute- and chronic-phase chronic myelogenous leukaemia: initial response and long-term results in 54 patients.
Niederle N; Moritz T; Kloke O; Wandl U; May D; Becher R; Franz T; Opalka B; Schmidt CG
Eur J Cancer; 1991; 27 Suppl 4():S7-14. PubMed ID: 1799485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
